Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®
Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents
Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million
Femasys Regains Compliance with Nasdaq Listing Requirements
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
Femasys received CE Mark approval for its FemHSG Catheter, expanding the company’s fertility diagnostics portfolio into the European market.